Scenario analyses (FF/UMEC/VI versus BUD/FOR), intent to treat population
| Base case | Scenario | FF/UMEC/VI ICER (cost per QALY gained) | |
| Base case | £1098 | ||
| Discount rate (costs, benefits) | 3.5% | 0.0% | £1547 |
| Discount rate (costs, benefits) | 3.5% | 5.0% | £900 |
| Within-trial mortality | On | Off | £1011 |
| Post-trial treatment effect | Off | On – 1 year | £255 |
| Post-trial treatment effect | Off | On – 3 years | Dominant |
| Post-trial treatment effect | Off | On – 5 years | Dominant |
| Post-trial treatment effect – waning | Off | On – 5 years | Dominant |
| Overall treatment discontinuation | On | Off | £1414 |
| Post-trial treatment discontinuation | On | Off | £1414 |
| Time horizon | Lifetime | Trial follow-up | Dominant |
| Replacement therapy | By treatment arm | By overall trial | £1098 |
| Perspective | Health service perspective | Societal perspective | £886 |
FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; BUD: budesonide; FOR: formoterol; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year.